Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Potentiating CD20 monoclonal antibody therapy by targeting complement C3 fragment covalently deposited on lymphoma cells.
Baskar S, Peng H, Gaglione EM, Carstens EJ, Lindorfer MA, Ahn IE, Herman SEM, Skarzynski M, Chang J, Keyvanfar K, Butera V, Blackburn AZ, Vire B, Maric I, Stetler-Stevenson M, Yuan CM, Eckhaus MA, Soto S, Farooqui MZH, Taylor RP, Rader C, Wiestner A. Baskar S, et al. Among authors: gaglione em. Blood. 2025 Jan 7:blood.2024024846. doi: 10.1182/blood.2024024846. Online ahead of print. Blood. 2025. PMID: 39774793
Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib.
Sun C, Nierman P, Kendall EK, Cheung J, Gulrajani M, Herman SEM, Pleyer C, Ahn IE, Stetler-Stevenson M, Yuan CM, Maric I, Gaglione EM, Harris HM, Pittaluga S, Wang MH, Patel P, Farooqui MZH, Izumi R, Hamdy A, Covey T, Wiestner A. Sun C, et al. Among authors: gaglione em. Blood. 2020 Jul 2;136(1):93-105. doi: 10.1182/blood.2019003715. Blood. 2020. PMID: 32202637 Free PMC article. Clinical Trial.
Risk-adapted, ofatumumab-based chemoimmunotherapy and consolidation in treatment-naïve chronic lymphocytic leukemia: a phase 2 study.
Desai S, Mo C, Gaglione EM, Yuan CM, Stetler-Stevenson M, Tian X, Maric I, Wake L, Farooqui MZ, Drinkwater DC, Soto S, Valdez J, Hughes TE, Nierman P, Lotter J, Marti GE, Pleyer C, Sun C, Superata J, Nichols C, Herman SEM, Lindorfer MA, Taylor RP, Wiestner A, Ahn IE. Desai S, et al. Among authors: gaglione em. Leuk Lymphoma. 2021 Aug;62(8):1816-1827. doi: 10.1080/10428194.2021.1888379. Epub 2021 Mar 2. Leuk Lymphoma. 2021. PMID: 33653216 Free PMC article. Clinical Trial.
NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenografts.
Zhang D, Harris HM, Chen J, Judy J, James G, Kelly A, McIntosh J, Tenn-McClellan A, Ambing E, Tan YS, Lu H, Gajewski S, Clifton MC, Yung S, Robbins DW, Pirooznia M, Skånland SS, Gaglione E, Mhibik M, Underbayev C, Ahn IE, Sun C, Herman SEM, Noviski M, Wiestner A. Zhang D, et al. Blood. 2023 Mar 30;141(13):1584-1596. doi: 10.1182/blood.2022016934. Blood. 2023. PMID: 36375120 Free PMC article.
Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting.
Mhibik M, Gaglione EM, Eik D, Herrick J, Le J, Ahn IE, Chiu C, Wielgos-Bonvallet M, Hiemstra IH, Breij ECW, Chen J, Reilly EB, Epling-Burnette PK, Szafer-Glusman E, Sun C, Wiestner A. Mhibik M, et al. Among authors: gaglione em. Blood Adv. 2023 Aug 8;7(15):4089-4101. doi: 10.1182/bloodadvances.2022009517. Blood Adv. 2023. PMID: 37219524 Free PMC article.
Overcoming Acquired Epigenetic Resistance to BTK Inhibitors.
Shaffer AL 3rd, Phelan JD, Wang JQ, Huang D, Wright GW, Kasbekar M, Choi J, Young RM, Webster DE, Yang Y, Zhao H, Yu X, Xu W, Roulland S, Ceribelli M, Zhang X, Wilson KM, Chen L, McKnight C, Klumpp-Thomas C, Thomas CJ, Häupl B, Oellerich T, Rae Z, Kelly MC, Ahn IE, Sun C, Gaglione EM, Wilson WH, Wiestner A, Staudt LM. Shaffer AL 3rd, et al. Among authors: gaglione em. Blood Cancer Discov. 2021 Sep 14;2(6):630-647. doi: 10.1158/2643-3230.BCD-21-0063. eCollection 2021 Nov. Blood Cancer Discov. 2021. PMID: 34778802 Free PMC article.
Patient-derived Siglec-6-targeting antibodies engineered for T-cell recruitment have potential therapeutic utility in chronic lymphocytic leukemia.
Cyr MG, Mhibik M, Qi J, Peng H, Chang J, Gaglione EM, Eik D, Herrick J, Venables T, Novick SJ, Courouble VV, Griffin PR, Wiestner A, Rader C. Cyr MG, et al. Among authors: gaglione em. J Immunother Cancer. 2022 Nov;10(11):e004850. doi: 10.1136/jitc-2022-004850. J Immunother Cancer. 2022. PMID: 36442911 Free PMC article.
14 results